Abivax S.A. (ABVX.PA) stock analysis

In our weekly check, Abivax S.A. is graded D (A to F). Of 19 checks on debt, profit, cash flow and trend: 7 pass, warnings: 1, red flags: 11.

About Abivax S.A.

Abivax S.A. is a Healthcare company (Biotechnology) based in France, listed on PAR as ABVX.PA.

What our checks show for ABVX.PA

Red flags

• Operating profit does not cover the interest bill (-9.8x): interest is paid from cash or new debt.
• Weak EPS forecast
• Analysts expect the net margin to shrink by 15.7 points from today's 0%.
• Weak EPS growth
• The net margin is only 0%: little room if costs rise.
• Free cash flow is negative (-18159489216% of revenue): the business spends more cash than it brings in.
• The price swings a lot: 101% annual volatility. Expect large ups and downs.
• The stock has fallen as much as 87% from a peak. Would you have held through that?
• The share count grew by 61.4% in 2 years: each shareholder owns a smaller slice.
• Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
• Pay in shares equals 0% of free cash flow: it dilutes shareholders.

Warning signs

• Thinly traded (about 133 thousand shares a day): buying and selling can move the price.

Strengths

• Debt is low: 0x equity.
• The net margin rose by 114735 points over 5 years, to 0%.
• After its deepest fall the stock recovered in about 3 months.
• Beta -0.23: the stock usually moves less than the market.

Next earnings report: 2026-12-14

Similar companies

AXSM · ARWR · IONS · TGTX · SYRE · PRAX

Questions

What grade does Abivax S.A. (ABVX.PA) have?

In our weekly check, Abivax S.A. is graded D (A to F). Of 19 checks on debt, profit, cash flow and trend: 7 pass, warnings: 1, red flags: 11. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of ABVX.PA stock?

This week's biggest flags for Abivax S.A.: Weak interest cover, Weak EPS forecast, Margins expected to shrink. In total 12 of 19 checks show a warning or a red flag.

What does Abivax S.A. do?

Abivax S.A. is a Healthcare company (Biotechnology) based in France, listed on PAR as ABVX.PA.

When does Abivax S.A. report earnings next?

The next earnings report is expected on 2026-12-14. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-24

Open the full analysis